Find the Right Market Report

Search thousands of industry reports, market insights, and research studies in one place.

Not sure where to start? Try one of these:
Explore healthcare market intelligence and industry insights
Towards Healthcare

Intravenous Iron Drugs Companies, Latest Offerings and Key Developments 2026

Date : 20 February 2026

Latest Updates of Key Players in the Intravenous Iron Drugs Market

Intravenous Iron Drugs Market Companies

Company Updates

Company Headquarters Latest Update
CSL Vifor Switzerland In September 2025, CSL Vifor and Travere Therapeutics, Inc., supported the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 healthcare practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis.
Daiichi Sankyo Company, Ltd. Japan Daiichi Sankyo is investing in major manufacturing expansion in the U.S. (Ohio) and China, which is primarily for ADC products.
Pharmacosmos A/S Denmark Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anaemia.
Sanofi S.A. France Sanofi S.A. is heavily focused on transitioning its portfolio toward high-growth immunology, rare disease, and vaccine products.
Fresenius Kabi AG Germany In December 2025, Fresenius announced the launch of its denosumab biosimilars, Conexxence and Bomyntra, in Europe
AbbVie Inc. United States In February 2026, AbbVie announced that it had submitted applications for an advanced indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib for the management of adult and adolescent patients living with non-segmental vitiligo.

Value Chain Analysis

R&D:

  • R&D processes in intravenous iron drugs involve preclinical formulation advancement and characterization, preclinical safety and efficacy testing, clinical trial development, and many other activities.
  • Key Players: CSL Vifor and Daiichi Sankyo Company, Ltd.

Manufacturing Processes:

Patient Services:

  • Key services involve a comprehensive, multi-stage process designed to safely and efficiently increase hemoglobin and iron levels when oral supplements are ineffective or unsuitable.
  • Key Players: Sanofi, Pharmacosmos A/S, and Fresenius Kabi AG

Market Growth Story

The global intravenous iron drugs market size was estimated at USD 3.65 billion in 2025 and is predicted to increase from USD 3.98 billion in 2026 to approximately USD 8.74 billion by 2035, expanding at a CAGR of 9.14% from 2026 to 2035.

Intravenous Iron Drugs Market Trends and Growth (2026)

Recent Developments in the Intravenous Iron Drugs Market

  • In November 2025, Viatris (VTRS) announced the FDA had approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to manage iron deficiency anemia in adult and pediatric patients with chronic kidney disease.
  • In September 2025, Sandoz, the worldwide leader in cost-effective medicines, announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA).
  • In August 2025, Viatris Inc., a global healthcare company, announced the U.S. Food and Drug Administration (FDA) had approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients with chronic kidney disease.

No scattered data, no confusion - manage all your Intravenous Iron Drugs Market services information in one place - Access the Dashboard

Ready to make better
healthcare business decisions?

Speak with a healthcare analyst about your research, consulting, or platform needs.

Talk to an Analyst Contact Sales